R21/Matrix-M malaria vaccine
Vacuna contra la malaria R21/Matrix-M
- Date
- 2021 · confidence high
- Place
- Nanoro, Centre-Ouest Region, Burkina Faso
- Credited to
- Halidou Tinto, Mehreen Datoo, Adrian Hill and colleagues (Jenner Institute, Oxford)
- Field
- Life & health
What was discovered
The Nanoro trial in children aged 5-17 months showed 77% efficacy for R21/Matrix-M in 2021, the first malaria vaccine to meet the WHO's 75% target. The WHO recommended it in 2023.
Phase 2b: 77% efficacy (high-dose adjuvant); phase 3 (2023) confirmed figures of 68-75%. Burkina Faso was the trial's centre.
What it led to
- expansion of malaria vaccination in Africa (2023-)
- production at the Serum Institute of India
- seasonal-use strategies